You don’t have products yet

View products

Advancements in Multiomics: Automation of Hyperion Staining on NanoVIP Reduces Hands-on Time and Reagent Costs by 90%

Omicsveu, The Spatial Multiplex Multiomics Company, announced introduction of a fully automated system for Hyperion’s multiplex immunohistochemistry (IHC) protocols developed and validated in collaboration with Scientists at The University of Sydney‘s prestigious Charles Perkins Centre, Sydney, Australia.

Tissue multiplexing technology has changed proteomics profiling, allowing for the simultaneous detection of multiple protein markers from a single tissue section. However, current technologies for multiplex-proteomics involve manual steps that are time-consuming, labor-intensive, expensive, and inconsistent.

NanoVIP – an automated, slide-based staining system – by Omicsveu using manufacturers supplied protocols and reagents, reduced hands-on time of the Hyperion protocol to less than 20 minutes and reagent costs by 80% – as it only uses 25µL of antibody for a single sample. Further NanoVIP plug & play system doesn’t require highly skilled operators to get optimum results. Results are summarized in the table below.

Adrian Smith, Technical Director at Sydney Cytometry (Centenary Institute and The University of Sydney), was so impressed with NanoVIP for the automated preparation of tissue sample slides. “We are very impressed with the instrument (and the support!), and I’m excited to see what our researchers at Sydney Cytometry will do with it!”  said Dr. Smith.

Results are summarized in the table below.

About Omicsveu

Omicsveu is a special-purpose spinoff of BioGenex, designs, develops, and commercializes, fully automated plug & play, slide-staining systems. Our innovative technologies are affordable and accessible, to help accelerate developments of new diagnostics and therapeutics leading to improved disease outcome. Our systems incorporate easy to use innovative automation, ready-to-use reagents, and optimized protocols, generating reliable, consistent, and reproducible results. For more information, please visit our website at www.omicsveu.com, or connect with us on LinkedIn and Twitter.

Share

Related News

By Omicsveu | November 1, 2022

Accelerating The Pace Of Spatial Biology
View All News

Advancements in Multiomics: Automation of Opal Staining on NanoVIP Saves 80% Reagent Cost and 90% Hands-on Time

The Spatial Multiplex Multiomics Company, announced the introduction of a fully automated system for Opal’s multiplex immunohistochemistry (IHC) protocols developed and validated in collaborations with scientists at multiple institutions.

 

Omicsveu has achieved a milestone with its NanoVIP instrument – a slide-based automated staining system – fully automating the Opal manual staining protocol from Akoya Biosciences. Using manufacturers supplied protocols and reagents, NanoVIP reduced the processing time of Opal’s protocol from over 48 hours to under 12 hours, hands-on time from 14 hours to less than 1 hour and reduces reagent consumption by 80%. Further NanoVIP plug & play system doesn’t require highly skilled operators to get optimum results. These substantial time and cost (material and labor) savings empower researchers to expedite their research projects, accelerate discoveries, and optimize laboratory workflows.

Omicsveu is committed to advancing scientific research to improve cancer survival rates and patients leading normal life,” said Dr. Krishan Kalra, CEO of Omicsveu. “By automating manual Opal protocol with NanoVIP, researchers achieve consistent, intense clean, crisp stains while saving time and reducing costs. This innovation sets a new benchmark in the spatial multiomics field.”

The results are summarized in the table below.

 

About Omicsveu: 

Omicsveu is a special-purpose spinoff of BioGenex, which designs, develops, and commercializes, fully automated plug & play, slide-staining systems. Our innovative technologies are affordable and accessible, to help accelerate development of new diagnostics and therapeutics leading to improved disease outcomes. Our systems incorporate easy-to-use innovative automation, ready-to-use reagents, and optimized protocols, generating reliable, consistent, and reproducible results. For more information, please visit our website at www.omicsveu.com, or connect with us on LinkedIn, and Twitter.

Share

Related News

By Omicsveu | November 1, 2022

Accelerating The Pace Of Spatial Biology
View All News

Accelerating The Pace Of Spatial Biology

Blog:

Fremont, USA – Nov 01, 2022 – We at OmicsVeu1 are pleased to introduce a broad line of spatial multi-omics products that are compatible with our fully automated NanoVIP® platform.

The current research trends rely on emerging technologies like spatial multi-omics, where we can simultaneously assess genomic, transcriptomic, and proteomic changes at a sub-cellular resolution in the same tissue section. These multi-dimensional approaches are instrumental in analyzing the tumor microenvironments, which comprise a heterogeneous population of cells, and biomarkers that actively track and depict cancer progression. Characterizing the cellular and molecular architecture of the tumor microenvironments render valuable insight which enables the discovery of new cancer-associated, and immunological biomarkers which help accelerate the discovery and development of new diagnostics and therapeutic regimens, says Dr. Krishan Kalra, CEO of OmicsVeu.

Accelerating The Pace Of Spatial Biology
Co-detection of mRNA (pink) & protein (green) on breast adenocarcinoma tissue

OmicsVeu offers a set of tools with the following fully automated spatial multi-omics technologies and protocols:

These five multi-omics tools with high multiplexing capabilities, encompass a fully automated All-in-One NanoVIP®2 instrument, ready to use all assay reagents with optimized protocols to generate high-throughput, high-quality, reproducible & reliable data sets. Our fully automated system is designed to automate any manual slide-based protocol including but not limited to, Genotyping and Phenotyping, In situ sequencing, eFISH, miRFISH, low, medium, high, and hyper Immuno-plex.

The system offers TEN independently programmable workstations which makes NanoVIP® an ideal system for protocol optimization. It is equipped with eXACT™ temperature modules (up to 105oC) and liquid-level sensors for accurate liquid dispensing to ensure robust and reproducible results. The NanoVIP® software is intuitive and easy-to-use to create user-defined protocols and store them for future use with unparalleled capabilities. With high-quality engineered hardware, unique features, and one of the smallest footprints in the market, the system remains an ideal choice for spatial multi-omics.

About OmicsVeu

We provide an unconditional product performance guarantee & premier customer support. NanoVIP® is easy to set-up plug and play system, a game changer for spatial multi-omics. We offer ready-to-use probes and multiplex antibodies along with visualization kits and all required consumables with fully optimized protocols to accelerate the pace of multi-omics research. Further NanoVIP® is an open system designed to automate any manual slide-based protocols with OmicsVeu or user-supplied reagents.

For further information contact:

48810 Kato Road,

Suite 100E & 200E, Fremont, CA 94538 USA

Tel: +1 510-824-1400

Email: customerservice@localhost

Watch Video: https://youtu.be/PhrPTmfJLGQ

Brochure: https://omicsveu.com/wp-content/uploads/Brochures/NanoVIP_Brochure_937-4124.0.pdf

1) OmicsVeu is a wholly owned subsidiary of BioGenex

2) NanoVIP® a fully automated staining system for FFPE, Frozen Tissues sections and Cyto-preps, provides slides ready for Imaging or for Imaging Mass Cytometer & CellProfiler.

Doc. no. 937-4126.0

Conclusion

In situ sequencing is a targeted image-based technology that can detect gene expression and provide location information within a cell sample or a tissue section. This tool is valuable for understanding the pathology and molecular mechanisms of diseases. So far, it has been applied in various areas, such as cancer diagnosis, gene expression profiling, and mutation detection. Providing gene expression images and spatial context using ISS results in an atlas-like map which has been used to develop The Human Developmental Cell Atlas. The project is a Swedish initiative developed by the Science for Life Laboratory, which aims to create a detailed molecular atlas of human cell types and show their spatial distributions in three dimensions.

References:

  • Chen, W.-T. et al. (2020) “Spatial transcriptomics and in situ sequencing to study alzheimer’s disease,” Cell, 182(4). Available at: https://doi.org/10.1016/j.cell.2020.06.038.
  • Hilscher, M.M. et al. (2021) “Correction to: In situ sequencing: A high-throughput, multi-targeted gene expression profiling technique for cell typing in tissue sections,” Methods in Molecular Biology [Preprint]. Available at: https://doi.org/10.1007/978-1-0716-0623-0_25.
  • In situ sequencing (2022) SciLifeLab. Available at: https://www.scilifelab.se/units/in-situ-sequencing/ (Accessed: December 4, 2022).
  • Ke, R., Mignardi, M., Pacureanu, A. et al. In situ sequencing for RNA analysis in preserved tissue and cells. Nat Methods 10, 857–860 (2013). https://doi.org/10.1038/nmeth.2563
  • The Human Developmental Cell Atlas (no date) HDCA Sweden. Available at: https://hdca-sweden.scilifelab.se/ (Accessed: December 4, 2022).

Share

Related News

View All News